Ichthyosis Clinical Trial
Official title:
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
The ichthyoses are a group of lifelong genetic disorders that share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. The vast majority are orphan disorders and are associated with extremely poor quality of life related to social ostracism from altered appearance, associated itchiness and discomfort, and functional limitations from the skin disease. Among the more common "orphan" forms of ichthyosis are autosomal recessive congenital ichthyosis (ARCI; includes lamellar ichthyosis/LI and congenital ichthyosiform erythroderma/CIE), Netherton syndrome (NS) and epidermolytic ichthyosis (EI). However, there are dozens of other syndromic and non-syndromic ichthyotic disorders as well. Therapy is time-consuming for patients or parents and is supportive, focusing on clearance of the scaling. There are no therapies based on our growing understanding of what causes the disease. We have recently found marked elevations in Th17/IL-23 pathway cytokines and chemokines in the skin of individuals with ichthyosis, most similar to the inflammatory pattern of psoriasis. While the significance of the high expression of Th17/IL-23 pathway genes across all forms of ichthyosis studied to date is unknown, the high expression of genes of the Th17/IL-23 pathway in psoriasis is thought to be causative for the disease manifestations. We propose that IL-12/IL-23 -targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life. As a proof-of-concept study, we propose to treat children (6 years of age and higher) and adults with ichthyotic disorders with ustekinumab in an open-label trial to serially assess clinical response to and safety of ustekinumab for this group of disorders.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03051347 -
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
|
N/A | |
| Completed |
NCT00004690 -
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
|
Phase 3 | |
| Completed |
NCT00074685 -
National Registry for Ichthyosis and Related Disorders
|
||
| Completed |
NCT03641261 -
Therapeutic Education Using an Internet Application in Hereditary Ichthyosis
|
N/A | |
| Completed |
NCT03796052 -
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
|
N/A | |
| Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
| Active, not recruiting |
NCT05295732 -
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
|
Phase 3 | |
| Terminated |
NCT02655861 -
A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
|
||
| Recruiting |
NCT03464994 -
Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)
|
N/A | |
| Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
| Terminated |
NCT04697056 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
|
Phase 2 | |
| Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
| Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
| Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
| Not yet recruiting |
NCT06362447 -
Efficacy of Injectable Gentamicin in Hereditary Ichthyosis
|
Phase 2 |